Altimmune, Inc. (ALT)Healthcare | Biotechnology | Gaithersburg, United States | NasdaqGM
3.11 USD
-0.13
(-4.012%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.12 +0.01 (0.367%) ⇧ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:33 a.m. EDT
The long-term investment case is severely compromised by a brutal multi-year decline; the stock has lost over 94% of its value since the observation window began, with five out of eight years showing negative returns. Despite a 'strong buy' analyst recommendation and a lofty price target, the underlying business shows no signs of recovery, posting negative operating margins and burning cash without generating revenue. The balance sheet, while currently liquid, is propped up by a recent capital raise that reshaped funding outlooks, yet the operational reality remains bleak. Short-term momentum is neutral to slightly bearish, with the price hovering near its 50-day average but failing to break out, while the options market screams caution with heavy put writing and elevated implied volatility on the downside. This is a classic value trap where the market has correctly priced out the deteriorating fundamentals, rendering any catalysts like upcoming data as insufficient to reverse the structural decline. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.047190 |
| AutoETS | 0.047289 |
| AutoARIMA | 0.047289 |
| AutoTheta | 0.078080 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 0.29 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.296 |
| Excess Kurtosis | -0.79 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2017-01-19 |
| Debt to Equity Ratio | 7.596 |
| Market Cap | 604,950,016 |
| Forward P/E | -4.65 |
| Beta | 0.17 |
| Website | https://altimmune.com |
As of Aug. 22, 2026, 5:33 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes at 1.0 and 2.0) across multiple expirations, while call activity remains thin and concentrated near the money. The implied volatility skew is extreme, with deep puts trading at significantly higher premiums than calls, indicating a market consensus of significant downside risk rather than a speculative rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.1706667 |
| Address1 | 910 Clopper Road |
| Address2 | Suite 201S |
| All Time High | 137.7 |
| All Time Low | 1.51 |
| Ask | 3.92 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 4,422,450 |
| Average Daily Volume3 Month | 4,390,779 |
| Average Volume | 4,390,779 |
| Average Volume10Days | 4,422,450 |
| Beta | 0.169 |
| Bid | 2.24 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 2.438 |
| City | Gaithersburg |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.11 |
| Current Ratio | 26.783 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.23 |
| Day Low | 3.0601 |
| Debt To Equity | 7.596 |
| Display Name | Altimmune |
| Dividend Date | 1,536,883,200 |
| Earnings Call Timestamp End | 1,786,537,800 |
| Earnings Call Timestamp Start | 1,786,537,800 |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -98,634,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.19 |
| Enterprise To Revenue | 10,151.26 |
| Enterprise Value | 314,689,056 |
| Eps Current Year | -0.58833 |
| Eps Forward | -0.66833 |
| Eps Trailing Twelve Months | -0.73 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,484,870,400 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.9832 |
| Fifty Day Average Change | 0.12679982 |
| Fifty Day Average Change Percent | 0.04250463 |
| Fifty Two Week Change Percent | -17.06667 |
| Fifty Two Week High | 6.44 |
| Fifty Two Week High Change | -3.3300002 |
| Fifty Two Week High Change Percent | -0.5170808 |
| Fifty Two Week Low | 2.56 |
| Fifty Two Week Low Change | 0.54999995 |
| Fifty Two Week Low Change Percent | 0.21484374 |
| Fifty Two Week Range | 2.56 - 6.44 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,495,805,400,000 |
| Float Shares | 164,390,799 |
| Forward Eps | -0.66833 |
| Forward P E | -4.6533895 |
| Free Cashflow | -48,786,124 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 57 |
| Fullday Change | -0.13 |
| Fullday Change Percent | -4.01235 |
| Fullday Price | 3.1214 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -66,693,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00416 |
| Held Percent Institutions | 0.77669 |
| Implied Shares Outstanding | 194,517,701 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.pharmathene.com/phoenix.zhtml?c=191999&p=irol-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,536,883,200 |
| Last Split Factor | 1:30 |
| Long Business Summary | Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. |
| Long Name | Altimmune, Inc. |
| Market | us_market |
| Market Cap | 604,950,016 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_4866807 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -91,760,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 630,237,351 |
| Number Of Analyst Opinions | 9 |
| Open | 3.21 |
| Operating Cashflow | -76,508,000 |
| Operating Margins | -3,184.9355 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Peg Ratio | 32.62 |
| Phone | 240 654 1450 |
| Post Market Change | 0.011400223 |
| Post Market Change Percent | 0.36656666 |
| Post Market Price | 3.1214 |
| Post Market Time | 1,787,961,541 |
| Previous Close | 3.24 |
| Price Eps Current Year | -5.286149 |
| Price Hint | 4 |
| Price To Book | 1.2756357 |
| Price To Sales Trailing12 Months | 19,514.518 |
| Profit Margins | 0.0 |
| Quick Ratio | 26.368 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | -0.13 |
| Regular Market Change Percent | -4.01235 |
| Regular Market Day High | 3.23 |
| Regular Market Day Low | 3.0601 |
| Regular Market Day Range | 3.0601 - 3.23 |
| Regular Market Open | 3.21 |
| Regular Market Previous Close | 3.24 |
| Regular Market Price | 3.11 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 3,187,399 |
| Return On Assets | -0.17198999 |
| Return On Equity | -0.28875 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 194,517,701 |
| Shares Percent Shares Out | 0.262 |
| Shares Short | 50,972,774 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 48,242,342 |
| Short Name | Altimmune, Inc. |
| Short Percent Of Float | 0.2624 |
| Short Ratio | 11.33 |
| Source Interval | 15 |
| State | MD |
| Symbol | ALT |
| Target High Price | 28.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 17.22222 |
| Target Median Price | 18.0 |
| Total Cash | 326,280,992 |
| Total Cash Per Share | 1.677 |
| Total Debt | 36,020,000 |
| Total Revenue | 31,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.73 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.670225 |
| Two Hundred Day Average Change | -0.560225 |
| Two Hundred Day Average Change Percent | -0.1526405 |
| Type Disp | Equity |
| Volume | 3,187,399 |
| Website | https://altimmune.com |
| Zip | 20,878 |